ADVA recognized as a Leaders Board Partner in the Intel® Network Builders’ Program
ADVA (FSE: ADV) today announced that it has been selected for the Intel® Network Builders Winners’ Circle Awards. ADVA was also one of a small number of companies to be recognized as part of the program’s Leaders Board with its Ensemble Connector virtualization platform, which was recently verified as an Intel® Select Solution for uCPE. The solution enables users to deploy a carrier-grade software layer that offers powerful performance and agile service provisioning. The award recognizes Ensemble Connector’s ability to deliver the benefits of network functions virtualization (NFV), support automated deployment at scale and turn the network edge into a platform for innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191014005430/en/
Prayson Pate, CTO, Edge Cloud, ADVA (Photo: Business Wire)
“We’re pleased to be working with Intel in its Intel Network Builders program and are proud to be recognized in the Winners’ Circle. Our collaboration on the Intel Select Solutions for uCPE program is bringing real value to our mutual customers in terms of a pre-integrated and validated solution,” said Prayson Pate, CTO, Edge Cloud, ADVA. “Our Ensemble Connector, integrated with Intel’s performance-optimized servers, is an ideal solution for demanding uCPE applications. It offers the power of the cloud with several key advantages such as zero-touch provisioning and platform security. Our Ensemble Connector also provides access to Ensemble Harmony, which includes a wide variety of onboarded commercial VNFs.”
The winners of this year’s awards were announced in The Hague, Netherlands, at the Intel® Network Builders Summit in conjunction with SDN NFV World Congress. Receiving the highest honor, Ensemble Connector is a powerful new software option for Intel Select Solutions for uCPE. It provides enhanced networking with advanced Layer 2 and 3 applications such as Carrier Ethernet 2.0 functionality, LTE access, and embedded routing and security features. The vendor-neutral platform eliminates supplier lock-in and ensures customers have a choice of best-of-breed components and deployment scenarios. The open and cloud-native Ensemble Connector also offers a platform for innovation at the edge, enabling adoption of advanced 5G and IoT applications.
Intel Network Builders is an ecosystem of independent software vendors, operating system vendors, original equipment manufacturers, telecom equipment manufacturers, system integrators, and communications service providers coming together to accelerate the adoption of NFV- and SDN-based solutions in telecommunications networks and public, private enterprise, and hybrid clouds. Intel Select Solutions for uCPE provides a foundation for the development of uCPE products with a solution reference design and verification of performance. These systems bring the powerful performance of Intel® Xeon® D processors to the edge of communication service provider networks for agile service provisioning.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191014005430/en/
Contact information
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom